 |
|
COMMENTS AND OPINIONS
The Case for Dual Renin-Angiotensin System Inhibition—Reply
Elaine Ku, MD;
Jeanie Park, MD;
Jay Vidhun, MD;
Vito Campese, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
Dr Hirsh raises some interesting points pertaining to our article on dual RAS.1 We agree with Dr Hirsh that the data from the ONTARGET2 trial do not address the issue of patients with proteinuria more than 1 g/d and should not be interpreted to completely dismiss these combinations. However, the available evidence shows that combination therapy with RAS inhibitors is more effective than single RAS blockade in reducing proteinuria, but there is no good evidence that these combinations are more effective than single RAS blockade when it comes to reducing chronic kidney disease progression. The ONTARGET trial should serve as a cautionary reminder that what is expected does not always translate into reality, and further studies are needed before combination therapy are routinely implemented in the treatment of chronic kidney disease.
The use of the angiotensin-converting . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease
Elaine Ku, Jeanie Park, Jay Vidhun, and Vito Campese
Arch Intern Med. 2009;169(11):1015-1018.
EXTRACT
| FULL TEXT
RELATED LETTERS
The Impact of Repeated Cycles of Pharmacotherapy on Smoking Cessation: A Longitudinal Cohort Study
A. Paula Cupertino, Jo A. Wick, Kimber P. Richter, Laura Mussulman, Niaman Nazir, and Edward F. Ellerbeck
Arch Intern Med. 2009;169(20):1928-1930.
EXTRACT
| FULL TEXT
The Case for Dual Renin-Angiotensin System Inhibition
Sheldon Hirsch
Arch Intern Med. 2009;169(20):1931.
EXTRACT
| FULL TEXT
|
